Pharma Focus Asia

Novel Plasma Technology Developed to Treat Multidrug Refractory Bacteria

Plasmology4® has developed a revolutionary, advanced, and specialised form of ‘non-thermal’ or ‘cold plasma’technology called ‘Plaz4®’.

Plasmology4® is harnessing the 4th state of matter i.e. plasma, to improve the quality of patients' lives worldwide. Plaz4 is designed to treat the multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed.

Plaz4 has the potential to destroy microbial cells including bacteria, fungi, and multidrug-resistant pathogens without harming the skin and soft tissues and has manyhealthcare applications, including the prevention and treatment of infections.By combining high voltage electricity with a non-combustible gas, glowing gas plasma is generated and delivered to wound tissues where it destroys pathogens. Plaz4®, while highly energized,is completely cool to the touch and cannot heat up tissues.

Besides, the results from initial pre-clinical studies of the plasma technology have shown a considerable decrease in antibiotic-resistant bacteria (MRSA) in a single topical treatment.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024